Legend Biotech Takes Two Oral Talks And Four Posters To ASH, Led By Early In Vivo CAR-T Data

The December meeting program covers CARVYKTI follow-up, an in vivo CAR-T study and an allogeneic lymphoma candidate.

Share
Legend Biotech Takes Two Oral Talks And Four Posters To ASH, Led By Early In Vivo CAR-T Data

Legend Biotech, which develops and sells cell therapies for cancer, will present updated first-in-human data on LB2501, an investigational in vivo CAR-T therapy, at the American Society of Hematology annual meeting in New Orleans, the company said Wednesday. In eight patients treated at dose level 2, overall and complete response rates were both 100%, with responses lasting up to five months as of the data cutoff.

A small cohort, an early signal

LB2501 is an off-the-shelf therapy designed to create CAR-T cells that target both CD19 and CD20 directly inside the patient. The 100% figure covers only the eight dose-level-2 patients in an ongoing Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma. The company said additional data from the study will be presented at the meeting.

The LB2501 poster is scheduled for December 13, alongside a poster on LUCAR-G39D, an allogeneic CD19/CD20 dual-targeting CAR-T candidate in the same lymphoma setting, which will carry follow-up Phase 1 findings.

CARVYKTI safety and durability

Legend's main product, CARVYKTI, is a CAR-T therapy for multiple myeloma that it develops with Janssen. Two oral talks on December 12 cover it.

The CITADEL study, a multicenter observational study, found a 1.6% rate of immune effector cell parkinsonism when a preemptive steroid strategy was used at four U.S. academic centers, against 2.9% in historical data. A CARTITUDE-4 subgroup analysis of patients refractory to lenalidomide and daratumumab found nearly 60% were progression-free 30 months after infusion, and median overall survival had not been reached.

The CARVYKTI label carries a warning from CARTITUDE-4: 29 of 208 patients (14%) in the CARVYKTI arm died within the first 10 months of randomization, versus 25 of 211 (12%) in the control arm.

The full ASH lineup

The program totals two oral presentations, four posters and one ePublication, at a meeting running December 12–15. Two CARVYKTI posters, on tumor burden at infusion in CARTITUDE-4 and on real-world early-line use in Europe and Brazil, are set for December 12. CEO Ingrid Zhang said the data reflect "the continued evolution of CARVYKTI and our work to advance the next generation of cell therapy."

The two CARVYKTI oral talks come first on December 12, and the LB2501 poster follows on December 13.

Sources

More on Legend Biotech

All Legend Biotech (LEGN) coverage →